Bill Sibold is Executive Vice President and
Head of Sanofi Genzyme, the specialty care
global business unit of Sanofi.
Previously, Bill was the Global Head of Sanofi Genzyme’s Multiple Sclerosis, Oncology and Immunology franchises, and led the preparation for the launches of two
important new immunology treatments.
Bill joined Sanofi Genzyme in 2011 as
Senior Vice President and Head of Multiple
Sclerosis, and oversaw the successful
launches of its two MS treatments. As Head
of Sanofi Genzyme, he leads the business’s
efforts to maintain its leadership in rare
diseases while continuing to grow in multiple sclerosis, oncology and immunology.
Bill has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions at Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology, and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Bill also served as Chief Commercial Officer of Avanir Pharmaceuticals.
Bill holds an MBA from Harvard Business
School and a bachelor’s in Molecular
Biophysics and Biochemistry from Yale
Executive Vice President and Head of Sanofi Genzyme